V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210003520 | 210006845 | 1.56 | 54.7 | Adjuvant (A) | 2019-03-07 | 2019-03-15 | FEC 100 | 02 | N | FEC | 100733045 |
| 210003521 | 210006846 | 1.76 | 88 | Palliative (P) | 2019-07-06 | 2019-11-02 | PACLITAXEL + TRASTUZUMAB | 02 | N | ABEMACICLIB + FULVESTRANT | 100132424 |
| 210003523 | 210006847 | null | null | null | 2019-08-01 | 2019-08-31 | null | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101699740 |
| 210003525 | 210006848 | 1.62 | 59 | Not known (9) | 2019-11-17 | 2019-11-27 | null | 01 | null | LETROZOLE + PALBOCICLIB | 100811853 |
| 210003527 | 210006849 | 1.72 | 0 | null | 2018-03-28 | 2018-03-28 | Paclitaxel+Trastuzumab wkly Maint | 02 | null | PACLITAXEL + TRASTUZUMAB | 101149906 |
| 210003532 | 210006852 | null | null | null | 2018-02-06 | 2018-02-07 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | null | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB | 100669115 |
| 210003533 | 210006853 | 1.54 | 102.2 | Palliative (P) | 2017-05-01 | 2017-05-15 | FEC 60 or 75 | N | N | FEC | 100241636 |
| 210003536 | 210006855 | 1.56 | 58.7 | Neo-adjuvant (N) | 2018-07-21 | 2018-07-30 | FEC 100 | 02 | N | FEC | 101491473 |
| 210003540 | 210006858 | null | null | null | 2016-09-30 | 2017-01-14 | FEC 100 | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100590453 |
| 210003542 | 210006860 | 1.68 | 0 | Adjuvant (A) | 2019-12-11 | 2019-12-14 | TRASTUZUMAB EMTANSINE | 02 | N | EC | 101043355 |
| 210003543 | 210006861 | 1.67 | 61 | null | 2021-08-02 | 2021-08-02 | Abemaciclib | null | null | FEC | 100446136 |
| 210003545 | 210006863 | 1.6 | 59.9 | Adjuvant (A) | null | 2018-06-26 | FEC + DOCETAXEL | null | null | FEC + DOCETAXEL | 100652043 |
| 210003547 | 210006864 | null | null | null | null | 2018-09-16 | Paclitaxel+Trastuzumab wkly Maint | 02 | null | PACLITAXEL + TRASTUZUMAB | 100127664 |
| 210003551 | 210006866 | 1.63 | 84.8 | null | 2018-01-25 | 2018-02-08 | FEC + DOCETAXEL | N | null | FEC + DOCETAXEL | 100945543 |
| 210003554 | 210006867 | null | null | null | 2017-12-22 | 2018-01-16 | EC | 02 | null | EC | 101431938 |
| 210003556 | 210006869 | 1.62 | 78.8 | Adjuvant (A) | 2016-03-22 | 2016-04-13 | FEC 100 | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100530539 |
| 210003557 | 210006870 | 1.64 | 65 | Adjuvant (A) | 2019-06-22 | 2019-06-24 | FEC 100 | N | Y | FEC | 101638505 |
| 210003559 | 210006871 | 1.67 | 62.3 | null | 2019-10-22 | 2019-11-17 | EC | 01 | null | EC | 101602883 |
| 210003561 | 210006873 | 1.57 | 60.4 | Palliative (P) | null | 2016-12-13 | null | null | N | CAPECITABINE | 100160981 |
| 210003564 | 210006876 | 1.58 | 61.4 | Neo-adjuvant (N) | null | 2017-12-09 | FEC 100 | null | N | FEC | 100430523 |
| 210003565 | 210006877 | 1.62 | 95 | null | 2017-03-25 | 2017-04-16 | FEC + DOCETAXEL | 02 | null | FEC + DOCETAXEL | 101379463 |
| 210003566 | 210006878 | 1.51 | 69.8 | null | 2018-10-27 | 2018-11-16 | null | null | null | CARBOPLATIN + GEMCITABINE | 101128317 |
| 210003567 | 210006879 | 1.61 | 74 | Adjuvant (A) | 2019-02-10 | 2019-02-22 | EC | null | N | EC | 100861637 |
| 210003571 | 210006881 | 1.7 | 85.4 | null | null | 2017-12-07 | Paclitaxel+Trastuzumab wkly Maint | null | null | PACLITAXEL + TRASTUZUMAB | 101595631 |
| 210003572 | 210006882 | 1.64 | null | Palliative (P) | null | 2018-05-09 | FEC 60 or 75 | N | N | FEC | 101700148 |
| 210003573 | 210006883 | 1.62 | 63.75 | null | 2017-03-13 | 2017-04-02 | FEC 60 OR 75 + DOCETAXEL | N | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 101729783 |
| 210003577 | 210006884 | 1.69 | 88 | Neo-adjuvant (N) | 2018-03-10 | 2018-03-22 | TCH (21 day Trastuzumab) Maint | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100430168 |
| 210003579 | 210006886 | null | 107.2 | null | null | 2019-08-04 | Trial Unspecified | null | null | PALBOCICLIB | 100932031 |
| 210003581 | 210006888 | null | 76.2 | Neo-adjuvant (N) | 2019-04-30 | 2019-07-25 | Capecitabine | 02 | N | FEC | 100435926 |
| 210003582 | 210006889 | 1.62 | 109 | Palliative (P) | 2015-10-04 | 2017-01-29 | FEC 100 | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101592335 |
| 210003587 | 210006893 | 1.56 | 64.4 | Palliative (P) | 2019-02-25 | 2019-03-10 | FEC 60 or 75 | null | N | FEC | 100491534 |
| 210003588 | 210006894 | 1.63 | 55.1 | Palliative (P) | 2018-05-19 | 2018-05-28 | FEC 100 | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100005171 |
| 210003590 | 210006896 | 0 | 72.8 | null | 2016-05-19 | 2016-06-02 | Epirubicin (weekly) | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100855551 |
| 210003595 | 210006901 | null | 76.4 | null | 2017-11-18 | 2017-12-03 | Letrozole + Palbociclib | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL + PERTUZUMAB + TRASTUZUMAB | 100773629 |
| 210003596 | 210006902 | null | null | null | 2017-05-05 | 2017-05-19 | FEC + DOCETAXEL | N | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100932729 |
| 210003598 | 210006904 | null | null | null | 2014-09-03 | 2016-03-11 | TRASTUZUMAB EMTANSINE | null | null | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100106900 |
| 210003602 | 210006908 | null | null | null | 2019-04-22 | 2019-04-28 | null | null | null | CAPECITABINE | 101661219 |
| 210003603 | 210006909 | 0 | 85.4 | Neo-adjuvant (N) | 2017-01-31 | 2017-02-06 | TRASTUZUMAB DERUXTECAN | 02 | N | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | 100567393 |
| 210003607 | 210006910 | null | null | null | 2018-05-11 | 2018-05-13 | Cyclophosphamide + Docetaxel | N | null | CARBOPLATIN + PACLITAXEL | 100594441 |
| 210003612 | 210006915 | 1.57 | 69.2 | Neo-adjuvant (N) | null | 2017-06-19 | Palbociclib | null | N | EC | 100548100 |
| 210003613 | 210006916 | 1.49 | 55.1 | Palliative (P) | 2017-10-22 | 2017-10-30 | null | null | N | ROSCO TRIAL | 100164255 |
| 210003614 | 210006917 | 1.67 | 65.9 | Adjuvant (A) | 2018-04-08 | 2018-04-22 | FEC 60 or 75 | N | N | FEC | 100051436 |
| 210003615 | 210006918 | 1.57 | 79 | Palliative (P) | 2021-07-07 | 2021-07-07 | Bevacizumab | null | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100399918 |
| 210003616 | 210006919 | null | null | null | 2018-12-27 | 2019-01-11 | FEC + DOCETAXEL | 02 | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 101600708 |
| 210003617 | 210006920 | null | null | null | 2019-05-03 | 2019-05-20 | FEC + DOCETAXEL | null | null | FEC + DOCETAXEL | 100006788 |
| 210003619 | 210006922 | 1.67 | 51 | Curative (C) | 2018-03-04 | 2018-05-18 | Paclitaxel+Trastuzumab wkly Maint | 02 | N | PACLITAXEL + TRASTUZUMAB | 100762088 |
| 210003622 | 210006924 | 1.59 | 54.7 | null | null | 2018-10-31 | FEC + DOCETAXEL | null | null | FEC + DOCETAXEL | 100628901 |
| 210003624 | 210006925 | 1.57 | 52.05 | null | 2019-09-05 | 2019-09-17 | Trial Unspecified | N | null | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100189033 |
| 210003628 | 210006928 | 1.41 | 63.5 | Palliative (P) | null | 2018-07-20 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100983156 |
| 210003629 | 210006929 | null | null | null | 2018-01-20 | 2018-01-27 | null | 02 | null | ATEZOLIZUMAB + NAB-PACLITAXEL | 101399238 |